Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Basal Health vs Claya

Basal Health
Graded #494

Lower grade

vs+15.099999999999994
Claya
Graded #267

Higher grade

The verdict

Claya takes it — 62.8/100 to 47.7/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBasal Health +3
45
42
Dose & formulationClaya +35
40
75
Clinical oversightClaya +34
48
82
Labs & monitoringClaya +3
50
53
FulfillmentClaya +9
58
67
Contract termsClaya +6
55
61
Basal Health · left barClaya · right bar

The numbers

MetricBasal HealthClaya
WeighScore47.7/10062.8/100
GradeCC
Scorecard rank#494#267
SemaglutideNot disclosed$299/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Basal Health

Graded #494 · C

Strengths

  • Stated nationwide coverage (50 states + DC)
  • Metabolic-framework positioning rather than single-product
  • Clinician-supervised dosing rather than a fixed protocol
  • Adaptive monitoring approach

Where it loses points

  • No pricing shown publicly — you must complete intake to see cost
  • Compounding pharmacy partner not named
  • GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
  • No LegitScript badge visible on the homepage
  • No FDA compounded-medication disclaimer on the pages reviewed
Claya

Graded #267 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard